BioVex is a privately held biotechnology company based in Woburn, Mass. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company’s lead product, OncoVEXGM-CSF is a first in class oncolytic vaccine. OncoVEXGM-CSF is currently being evaluated in a Phase 3 multi-national study in metastatic melanoma and a Phase 3 study in head and neck cancer is scheduled to commence in the second half of 2010. BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date.

The Company has recently also commenced clinical testing in the UK with its vaccine candidate for the prevention and potentially the treatment of genital herpes.

BioVex recently closed a $70m funding round representing the second largest venture capital raise in the biotech sector in 2009.

BioVex Management

President, Chief Executive Officer and Director:
Mr Philip Astley-Sparke

Philip Astley-Sparke established BioVex's headquarters and operations in the US in 2004 and prior to becoming CEO served as the Company's President & COO. Prior to joining the Company, initially as CFO, in 2000, Mr. Astley-Sparke was in healthcare corporate finance at Chase H&Q (Robert Fleming) where he advised on numerous high profile fundraisings and mergers and acquisitions in the biotech sector. He received his B.S. in Cellular & Molecular Pathology from Bristol University and qualified as a Chartered Accountant with Arthur Andersen.

Chief Technology Officer, Founder and Director:
Dr Robert Coffin

Robert Coffin, Ph.D. founded BioVex in 1999, and is our Chief Technology Officer. Prior to founding BioVex Dr. Coffin oversaw a research group at University College London studying basic virology and developing virus-based technology for exploring fundamental biological processes and the development of therapeutic products. Dr Coffin has authored more than 60 scientific papers and is an inventor on all the patents protecting BioVex's technology. Since founding BioVex, Dr Coffin has managed BioVex's research and development, taking multiple products from initial inception through clinical trials, including Phase III.

Chief Financial Officer, Treasurer and Secretary:
Stephen Gorgol

Stephen Gorgol has served as our head of Finance and Administration since May 2005. Prior to joining us, Mr. Gorgol was at Vista Medical Technologies, Inc., a NASDAQ traded medical device manufacturer, from 1997 to 2004 where he served as CFO. He received his B.S. in Accounting from Plymouth State University, New Hampshire.

SVP Product Development:
Dr Colin Love

Colin Love, Ph.D. , has served as our Senior Vice President, Product Development since 2000. Dr. Love was Director of Manufacturing Development at the Celltech Group, a global biopharmaceutical company, where he worked from 1992 to 2000. Dr. Love received a B.Sc. in biochemistry and a Ph.D. from Glasgow University.

Chief Medical Officer:
Howard Goldsweig, MD

Howard Goldsweig, MD, joined BioVex in March 2008 as Chief Medical Officer. He is board-certified in Medical Oncology. He came to BioVEX from Averion Internationl, where he was Therapeutic Area Head for Oncology. Previously, he had held various positions of increasing responsibility with several biopharmaceutical companies including Wyeth-Ayerst and Hoffmann La Roche. Dr. Goldsweig is a Dean’s List Graduate of Franklin and Marshall College. He received his medical degree from the State University of New York, Downstate Medical Center, completing his medical residency at McGill University and fellowship in medical oncology at the McGaw Cancer Center of Northwestern University. Earlier in his career, he held faculty positions and was an attending physician at both Columbia-Presbyterian Medical Center and St Luke’s Roosevelt Hospital Center in New York City.

VP Operations:
Lance Weed

Lance Weed joined BioVex Inc. in April of 2006 as the Director of Operations with the responsibility of managing the build out of the Woburn facility. He was promoted to Vice President of Operations in 2007. Previously, Lance was the Director of Operations at Formatech Inc. from 2004 and was responsible for all operational activities related to the contract aseptic filling suite and the facility maintenance. Lance began his career at Biopure Inc. in 1987and advanced though positions in manufacturing, engineering and management to become the Director of Manufacturing Operations. He gained experience through multiple plant expansions and was responsible for start up and operation of two remote manufacturing facilities during his development. Lance holds a degree in Chemical Engineering.

VP of CMC (Chemistry, Manufacturing & Control):
Paul Bullock

Paul Bullock joined BioVex in 2001 as the Head of Analytical Development and since then has been central to the product development of BioVex’s products. Paul leads the groups responsible for process development, technology transfer, scale-up, quality control and product characterization. As Director of CMC Development he managed the successful transfer of the OncoVEXGM-CSF manufacturing process from European CMO to the BioVex Woburn site. He was promoted to VP of CMC in 2009. Previously he worked in product development roles at Medeva and the Celltech Group and holds a degree in Molecular Biology.

Chief Commercial Officer
Steven Kelly

Mr. Kelly began his career at Amgen as a process development and manufacturing scientist. Steve then moved within Amgen into new product marketing where he was responsible for all aspects of launch planning for a third market entrant into the interferon market before taking responsibility for promotion and medical education for the commercial development of Epogen. In 1996, Steve joined IDEC Pharmaceuticals as head of marketing and oversaw the launch of Rituxan, the first monoclonal antibody to be approved by the FDA. Steve was also responsible for managing the Rituxan partnership with Genentech. In 2002 Steve joined Sanofi as their first head of oncology marketing for the US charged with building oncology expertise in a Company new to this therapeutic class. Steve oversaw the launch of Eloxatin, a third generation platinum compound for colorectal cancer. Eloxatin became the most successful oncology launch at the time with nearly $400m of sales in the first 12 months. Most recently, Steve was CEO of Innovive Pharmaceuticals, an oncology drug development company.

VP, Commercial Operations:
Tim Hanke

Mr. Hanke joins BioVex from Tiba Oncology where he held a senior leadership position in this leading oncology market research organization.  He previously served as Director of Global Commercial Operations at Genta after heading their Sales Training and Development functions.  Earlier in Tim’s career he held a variety of sales and marketing positions with increasing responsibilities at Chiron Biopharmaceuticals including market development roles in the U.S., Latin America, South Africa and Asia.  He began his career in marketing at Berlex Laboratories where he worked on the launch of Fludara® for hematological malignancies.

VP, Regulatory Affairs and Quality Assurance:
Anne Marie Woodland

Anne Marie Woodland joined BioVex in May 2009 as Vice President, Regulatory Affairs and Quality Assurance. Prior to joining us, Ms. Woodland served as Executive Director, Quality and Regulatory Affairs at CombinatoRx, Inc. Prior to CombinatoRx, she was Senior Director, Quality at Dyax Corp. She has also held positions at Curis Inc. (previously Reprogenesis), T-Cell Diagnostics and Baxter Dade. Ms. Woodland completed a B.S. in Medical Technology at Fitchburg State College and a M.S. in Management at Lesley College.

 

BioVex Board of Directors

President, Chief Executive Officer and Director: Philip Astley-Sparke

Philip Astley-Sparke established BioVex's headquarters and operations in the US in 2004 and prior to becoming CEO served as the Company's President & COO. Prior to joining the Company, initially as CFO, in 2000, Mr. Astley-Sparke was in healthcare corporate finance at Chase H&Q (Robert Fleming) where he advised on numerous high profile fundraisings and mergers and acquisitions in the biotech sector.

He received his B.S. in Cellular & Molecular Pathology from Bristol University and qualified as a Chartered Accountant with Arthur Andersen.

Chief Technology Officer, Founder and Director: Dr Robert Coffin

Robert Coffin, Ph.D. is one of our founders and our Chief Technology Officer, prior to which served as our Chief Scientific Officer since 1999. He is an expert in the application of virus-based technology for the development of therapeutic products, has authored more than 60 scientific papers and is an inventor on all the patents protecting Biovex's technology.

Dr. Coffin received his Ph.D. in 1991 from Imperial College, London.

Dr. Stephen Reeders

Steve founded MVM in 1997. Prior to setting up MVM, he was responsible for early-stage healthcare investments at Saunders, Karp & Megrue in New York City. Between 1988 and 1993 Steve was an Investigator of the Howard Hughes Medical Institute at the Boyer Center for Molecular Medicine at Yale, where he was also an Associate Professor of Medicine and Genetics. He has published more than 50 papers on the molecular genetics of human disease.

Steve has been involved in starting several US biotechnology companies and was acting CEO at UpToDate In Medicine in Wellesley, Mass. He practised medicine at the John Radcliffe Hospital, Churchill Hospital, Guys Hospital, St Thomas's Hospital, Hammersmith Hospital and the Institute of Neurology, Queen Square before taking up research into molecular genetics at Oxford University. He has a degree in Natural Sciences from Cambridge and a Doctorate in medicine from Oxford and is a member of the Royal College of Physicians of England.

Steve is a member of the boards of Biomedix, Inc., BioVex Group, Inc., Cara Therapeutics, Inc. and Cortria Corporation. He was previously a director of Clavis Pharma ASA, Domantis Ltd, Gendaq Ltd, Momenta Pharmaceuticals, Inc., New Chemical Entities, Inc., Nova Science Ltd., Sangamo Biosciences, Inc., Spherics, Inc., UpToDate, Inc., and Xention Ltd.

Sander Slootweg

Sander Slootweg co-founded Forbion Capital Partners is 2006 and is currently Managing Partner at Forbion. He serves on the boards of Biovex, Inc. (Woburn, Massachusetts), Xention Discovery Ltd (Cambridge, UK) and Pulmagen Therapeutics (formerly Argenta Discovery, Harlow UK). During recent years, he was the Chairman of AMT N.V. (Amsterdam, Netherlands / Euronext: AMT), board member at Fovea Pharmaceuticals (sold to Sanofi in 2009), board member at Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), board member at Impella Cardiosystems AG. (sold to Abiomed, Inc. in 2005), board member at Glycart AG (sold to Roche in 2005), board member at Cambridge Drug Discovery Ltd (sold to Biofocus Plc in 2001), board member at Pieris AG, Cilian AG and AM Pharma B.V.

Before co-founding Forbion Capital Partners, he was an Investment Director at ABN AMRO Capital Life Sciences (Netherlands) from which Forbion was spun out. Before, also at ABN AMRO Capital, Sander worked in the buy-out/ growth equities team. His other roles at ABN AMRO Bank included Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Latin America (Regional Office Miami).

Sander Slootweg holds an MSc from the Free University of Amsterdam in Business and Financial Economics and a degree in Business Administration from Nijenrode University, The Netherlands.

Somu Subramaniam

Somu Subramaniam is the Managing Partner of New Science Ventures (NSV), which he co-founded in 2004. NSV focuses on science-based venture investments in biotechnology, medical device and semiconductor sectors, and manages over $100 million and over 20 portfolio companies.  Mr. Subramaniam serves on several Board of Directors, including Therox, a company that has developed a focal hyperoxemic technology designed to treat ischemic myocardial tissue in heart attack patients; Receptor Biologix, a biotechnology company focused on the development of biotherapeutics designed to modulate the receptor tyrosine kinase (RTK) family of cell-surface receptors; and Achronix a fabless semiconductor company building the world’s fastest FPGAs.  He also is an observer to the boards of Light Sciences Oncology, Xoft and BioProcessors.  Prior to starting NSV, Somu was a Director of McKinsey & Co. and at various times led their Strategy Practice, BioTechnology Practice and HealthCare Practice. He also was a member of McKinsey's Investment Committee.

Somu received his undergraduate degree from B.Tech. from IIT and his M.B.A. from Harvard Business School.

Sebastien Cleftie

J. Sebastien Cleiftie, Investment manager with Innoven Partenaires, has 10 years of scientific research, business development, and venture capital investment experience in the life sciences sector. He started his career as a scientist in immunotherapy and gene therapy pre-clinical research at Aventis Pharma (now sanofi-aventis) in California, and subsequently provided strategic and business development consulting services to several biotechnology firms in the US and Europe. Since joining Innoven Partners, J. Sebastien has been involved in numerous life science venture capital transactions including Paion (Frankfort Stock Exchange: PA8), BioVex, OctoPlus (Euronext:OCTO.AS), and EyeGate Pharma. He currently serves on the board of 5 venture-backed companies.

He has a BS in Biomedical Sciences and an MS in Immunology from University of Paris V, and an MBA from Cornell University.

Reenie McCarthy

Reenie McCarthy has represented Morningside since 1993 and has extensive experience with venture backed biotechnology companies. Morningside is a diversified investment group with investments in North America, Europe, across Asia-Pacific, and, since 1992, in Mainland China.  Ms. McCarthy received her A.B., cum laude, from Bates College and her J.D. from the University of Pennsylvania Law School. Prior to joining Morningside in 1993, Ms. McCarthy was with Richards & O’Neill (now Bingham McCutcheon LLP) in New York. She currently represents Morningside on several private company boards.

Investors

• Forbion
• Avalon Ventures
• Credit Agricole Private Equity
• GeneChem Management
• Harris & Harris Group
• Innoven Partenaires
• Lloyds TSB Development Capital
• New Science Ventures
• Scottish Equity Partners
• Omega Partners
• Triathlon Medical Ventures
• Morningside Venture
• Ventech
• MVM Life Science Partners
• Sectoral Asset Management
• Ysios Capital Partners